News & Updates

Show Multimedia Only
Safinamide for Parkinson’s: Dyskinesia up short term, motor symptoms down long term

Safinamide for Parkinson’s: Dyskinesia up short term, motor symptoms down long term

12 Oct 2022 byNatalia Reoutova

A post-hoc analysis of a phase III trial of long-term safinamide for Parkinson’s disease (PD) finds a significant early increase in pre-existing dyskinesia as well as improved motor symptoms in patients with or without pre-existing dyskinesia at 1 year.

12 Oct 2022
Dimethyl fumarate bests interferon β-1a in paediatric-onset multiple sclerosis Dimethyl fumarate bests interferon β-1a in paediatric-onset multiple sclerosis

Dimethyl fumarate bests interferon β-1a in paediatric-onset multiple sclerosis

10 Oct 2022

The use of dimethyl fumarate (DMF) in the treatment of children with paediatric-onset multiple sclerosis (POMS) appears to produce more favourable effects than interferon β-1a (IFNβ-1a), with those on DMF being less likely to have new or newly enlarging lesions and experience relapse, according to data from the open-label CONNECT study.

10 Oct 2022
AF increases susceptibility to stroke associated with air pollution exposure

AF increases susceptibility to stroke associated with air pollution exposure

30 Sep 2022 byJairia Dela Cruz

Atrial fibrillation (AF) exacerbates the effect of air pollution exposure on acute ischaemic stroke outcomes, such that AF patients are more likely to develop stroke when exposed to increasing levels of smog (O3) and carbon monoxide (CO) compared with those who have no AF, according to a Singapore study.

30 Sep 2022